
A nasal spray solution containing human IgG1 antibodies against SARS-CoV-2 (NAS) demonstrated potent neutralizing activity against various virus variants. Biocompatibility assessments revealed safety, and intranasal administration in rats showed no circulatory presence of antibodies. A human trial confirmed NAS's safety and ability to increase neutralizing antibodies in nasal fluids, lasting at least 6 hours post-application.
Like
Save
Share